Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Belinda Wickihalder"'
Autor:
Julia Tietz, Tea Gunde, Stefan Warmuth, Christopher Weinert, Matthias Brock, Alexandre Simonin, Christian Hess, Maria Johansson, Fabio Spiga, Simone Muntwiler, Belinda Wickihalder, Dana Mahler, Dania Diem, Julia Zeberer, Robin Heiz, Naomi Flückiger, Noriko Shiraishi, Yoshihide Miyake, Nobuaki Takahashi, Markus Fehrholz, Marta Bertolini, Peter Lichtlen, David Urech, Daniel Snell
Publikováno v:
JID Innovations, Vol 4, Iss 2, Pp 100258- (2024)
Inhibition of IL-4/IL-13 signaling has dramatically improved the treatment of atopic dermatitis (AD). However, in many patients, clinical responses are slow to develop and remain modest. Indeed, some symptoms of AD are dependent on IL-31, which is on
Externí odkaz:
https://doaj.org/article/3a75a4014dc34c0e9ce5224f697c7026
Autor:
Stefan Warmuth, Tea Gunde, Daniel Snell, Matthias Brock, Christopher Weinert, Alexandre Simonin, Christian Hess, Julia Tietz, Maria Johansson, Fabio Mario Spiga, Robin Heiz, Naomi Flückiger, Sandro Wagen, Julia Zeberer, Dania Diem, Dana Mahler, Belinda Wickihalder, Simone Muntwiler, Bithi Chatterjee, Benjamin Küttner, Bettina Bommer, Yasemin Yaman, Peter Lichtlen, David Urech
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Co-stimulatory 4–1BB receptors on tumor-infiltrating T cells are a compelling target for overcoming resistance to immune checkpoint inhibitors, but initial clinical studies of 4–1BB agonist mAbs were accompanied by liver toxicity. We sought to en
Externí odkaz:
https://doaj.org/article/2cef15a66dc442d1a31020e1730a9800
Autor:
Hitesh Mistry, Fernando Ortega, Bithi Chatterjee, Nicole Bassler, Niels Kirk, Julia Tietz, Belinda Wickihalder, Simone Muntwiler, Simon Carnal, Daniel Snell, Christophe Chassagnole
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ec3022adef995026ce43df33572a47d
https://doi.org/10.1136/jitc-2022-sitc2022.1293
https://doi.org/10.1136/jitc-2022-sitc2022.1293
Autor:
Stefan Warmuth, Tea Gunde, Daniel Snell, Matthias Brock, Christopher Weinert, Alexandre Simonin, Christian Hess, Julia Tietz, Maria Johansson, Fabio Mario Spiga, Robin Heiz, Naomi Flückiger, Sandro Wagen, Julia Zeberer, Dania Diem, Dana Mahler, Belinda Wickihalder, Simone Muntwiler, Bithi Chatterjee, Benjamin Küttner, Bettina Bommer, Yasemin Yaman, Peter Lichtlen, David Urech
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Co-stimulatory 4–1BB receptors on tumor-infiltrating T cells are a compelling target for overcoming resistance to immune checkpoint inhibitors, but initial clinical studies of 4–1BB agonist mAbs were accompanied by liver toxicity. We sought to en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c65a392b42386048d75da1b31b47ae5
https://pubmed.ncbi.nlm.nih.gov/35844969
https://pubmed.ncbi.nlm.nih.gov/35844969
Autor:
Daniel Snell, Tea Gunde, Stefan Warmuth, Peter Lichtlen, Linlin Liu, Shu-wen Teng, Lan Zhang, ChaoHsuan Pan, Peiqi Li, Julia Tietz, Matthias Brock, Alexandre Simonim, Christian Hess, Christopher Weinert, Maria Johansson, Bithi Chatterjeee, Nicole Bassler, Niels Kirk, Catia Mendes, Robin Heiz, Naomi Flueckiger, Dania Diem, Dana Mahler, Belinda Wickihalder, Simone Muntwiler, Sandro Wagen, Elmar vom Baur, Archie N. Tse, David Urech
Publikováno v:
Cancer Research. 82:2870-2870
Antagonistic molecules targeting the PD-1/PD-L1 axis have shown excellent activity in the clinic. However, the majority of patients do not respond to the therapy due to multifaceted reasons implicating a non-effective activation of the immune system
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c66e2a2e3962a5347dc40d5b43afcb4
https://doi.org/10.1158/1538-7445.am2022-2870
https://doi.org/10.1158/1538-7445.am2022-2870
Autor:
Bithi Chatterjee, Christian Hess, Daniel Snell, Tea Gunde, Stefan Warmuth, Alexandre Simonin, Matthias Brock, Fabio Spiga, Maria Johansson, Christopher Weinert, Julia Tietz, Niels Kirk, Nicole Bassler, Dana Mahler, Dania Diem, Alessandra Carrella, Noreen Giezendanner, Alessandra Alberti, Giorgio Gambino, Belinda Wickihalder, Bettina Bommer, Simone Muntwiler, Yasemin Yaman, Naomi Flueckiger, Robin Heiz, Sandro Wagen, David Urech
Publikováno v:
Cancer Research. 82:2871-2871
CD3-based T cell engagers are highly potent therapeutic molecules which enable T cell-mediated cytotoxic activity toward cells expressing selected tumor-associated antigens. Alongside a highly potent anti-tumor activity, is the risk of on-target off-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c7a4c193bb3250337bc2d869247fe0e
https://doi.org/10.1158/1538-7445.am2022-2871
https://doi.org/10.1158/1538-7445.am2022-2871
Autor:
Antonia Poelderl, Peter Lichtlen, Julia Zeberer, Naomi Flueckiger, Tea Gunde, Dana Mahler, Alexandre Simonin, Robin Heiz, Diego Morenzoni, Simone Muntwiler, Matthias Brock, Sandro Wagen, Benjamin Kuettner, Daniel Snell, Stefan Warmuth, Christian Hess, Dania Diem, Julia Tietz, David Urech, Timothy Egan, Weinert Christopher, Belinda Wickihalder, Sebastian Meyer
Publikováno v:
Cancer Research. 80:2276-2276
Antagonistic molecules targeting the PD-1/PD-L1 axis have shown excellent activity in the clinic. However the majority of patients do not respond to the therapy due to multifaceted reasons implicating a non-effective activation of the immune system i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a58b38f496d759f563a625087a7193e
https://doi.org/10.1158/1538-7445.am2020-2276
https://doi.org/10.1158/1538-7445.am2020-2276
Autor:
Tea Gunde, Matthias Brock, Stefan Warmuth, Alexandre Simonin, Christian Hess, Eva Oswald, Julia Tietz, Julia Zeberer, Dana Mahler, Simone Muntwiler, Benjamin Küttner, Belinda Wickihalder, Antonia Pölderl, Dania Diem, Teddy Beltrametti, Robin Heiz, Sebastian Meyer, Timothy Egan, David Urech
Publikováno v:
Cancer Research. 79:1532-1532
The combined immunomodulation of PD-L1/PD-1 and 4-1BB is considered a promising strategy to increase response rates among cancer patients who are eligible to receive PD-L1/PD-1 inhibitors. Unfortunately, encouraging pre-clinical results achieved with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0da86f1d5a159fe4363b8b691327bdea
https://doi.org/10.1158/1538-7445.am2019-1532
https://doi.org/10.1158/1538-7445.am2019-1532